Organon (OGN) EBIT (QoQ) (2020 - 2026)
Organon (OGN) EBIT (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.25 Bn | 628.49 Bn | 17.26 Bn |
| 2 | AbbVie | 466.16 Bn | 459.59 Bn | 12.70 Bn |
| 3 | Merck | 374.06 Bn | 366.92 Bn | 12.21 Bn |
| 4 | Novartis Ag | 299.37 Bn | 291.68 Bn | 11.24 Bn |
| 5 | Astrazeneca | 256.40 Bn | 251.50 Bn | 12.86 Bn |
| 6 | Amgen | 235.27 Bn | 221.28 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 180.36 Bn | 177.18 Bn | 6.22 Bn |
| 8 | Pfizer | 159.69 Bn | 147.99 Bn | 10.94 Bn |
| 9 | Gsk | 105.08 Bn | 100.92 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.45% |
| Mar 31, 2026 | 11.90% |
| Dec 31, 2025 | -41.34% |
| Sep 30, 2025 | 10.49% |
| Jun 30, 2025 | 35.56% |
| Mar 31, 2025 | -17.01% |
| Dec 31, 2024 | -29.93% |
| Sep 30, 2024 | 6.48% |
| Jun 30, 2024 | 189.98% |
| Mar 31, 2024 | 25.91% |
| Dec 31, 2023 | -8.83% |
| Sep 30, 2023 | -37.82% |
| Jun 30, 2023 | -11.88% |
| Mar 31, 2023 | 28.57% |
| Dec 31, 2022 | -79.55% |
| Sep 30, 2022 | 10.63% |
| Jun 30, 2022 | -152.94% |
| Mar 31, 2022 | 67.22% |
| Dec 31, 2021 | -65.00% |
| Sep 30, 2021 | -50.68% |